Carmell to merge with regenerative medicine company Axolotl

Axolotl shareholders will receive an initial equity value of $65m and up to $75m in potential milestone equity payments.

RanjithKumar Dharma July 28 2023

Carmell Therapeutics has entered a definitive agreement and plan of merger with the regenerative medicine company Axolotl Biologix.

Axolotl's shareholders will receive an initial equity value of $65m.

They will also potentially receive $75m in milestone equity payments linked to reaching revenue and business milestones.

Axolotl CEO Josh Sandberg stated: “I am excited to partner with Rajiv and Carmell to build on our shared vision of offering industry-leading products that positively impact patients’ lives. Our teams have worked very diligently, and this transaction creates unlimited possibilities.”

Axolotl focuses on designing, developing and selling human amnion-based allograft products for active soft tissue repair, aesthetics and orthopaedic applications.

The company is currently enrolling participants for a Phase I/II clinical trial aimed at treating ankle osteoarthritis.

It is also working on the development of a topical cosmeceutical product designed to rejuvenate the skin.

On 30 June 2023, Axolotl's unaudited trailing 12-month (TTM) net revenue was $50m, with unaudited TTM earnings before interest, taxes, depreciation and amortisation from product sales reaching $5m.

Carmell executive chairman Rajiv Shukla stated: “I look forward to working with Josh and the Axolotl team to accelerate our goal of building Carmell into an industry-leading regenerative medicine company through a combination of in-house product development, bolt-on acquisitions and business development aimed at aesthetics/soft tissue and orthopaedic indications.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close